Loading
NASDAQHealthcareBiotechnology
Latest quote
$8.01
−$0.09 · -1.11%
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Latest quote
$8.01
−$0.09 · -1.11%
After-hours
$8.01
$0.00 · 0.00%
Oct 8, 6:08 PM ET
Regular session · ET · Market data may be delayed.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Day range
Current $8.01
52-week range
Current $8.01
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
30
Expensive
Sentiment
69
Bullish
Risk
59
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Day range
Current $8.01
52-week range
Current $8.01
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 22.27M USD | 25.18M USD | 2.55M USD | 244.9K USD |
| Cost of goods sold | — | 49.97M USD | 36.45M USD | 21.82M USD | — |
| Gross profit | — | −27.7M USD | −11.27M USD | −19.27M USD | 244.9K USD |
| Research and development | 84.45M USD | 49.97M USD | 36.45M USD | 21.82M USD | 13.57M USD |
| Selling, general, and administrative | 22.75M USD | 14.87M USD | 12.81M USD | 10.43M USD | 7.61M USD |
| Operating expenses | 108.14M USD | 14.87M USD | 12.81M USD | 10.43M USD | 21.18M USD |
| Interest income | 6.26M USD | 2.2M USD | 1.73M USD | 521.53K USD | — |
| Interest expense | 3.05M USD | — | — | — | — |
| Depreciation and amortization | 1.89M USD | 1.43M USD | 1.07M USD | 533.13K USD | 245.7K USD |
| Operating income | −108.14M USD | −42.56M USD | −24.08M USD | −29.7M USD | −20.94M USD |
| Net income | −105.04M USD | −40.47M USD | −22.29M USD | −29.02M USD | −20.02M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.70
58.55% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
